To investigate the role of phospholipase C (PLC), phospholipase A 2 (PLA 2 ), calcium, and protein kinase C (PKC) in mediating leptin-enhanced aggregation of human platelets. DESIGN: In vitro, ex vivo study. SETTING: Outpatient's Service for Prevention and Treatment of Obesity at the University Hospital of Messina, Italy. SUBJECTS: In total, 14 healthy normal-weight male (age 31.471.9 y; body mass index 22.770.6 kg/m 2 ) subjects. MEASUREMENTS: Adenosine diphosphate-(ADP-) induced platelet aggregation and platelet free calcium were measured after incubation of platelets with leptin alone (5-500 ng/ml), or leptin (50 and 100 ng/ml) in combination with anti-human leptin receptor long form antibody (anti-ObRb-Ab, 1:800-1:100 dilutions), PLC inhibitor U73122 (3.125-25 mM), PLA 2 inhibitor AACOCF3 (1.25-10 mM), or PKC inhibitor Ro31-8220 (1.25-10 mM). RESULTS: Platelet stimulation with leptin leads to a significant and dose-dependent increase in ADP-induced platelet aggregation and platelet free calcium concentrations. Leptin effects on both platelet aggregation and calcium mobilization were completely abated by the co-incubation with leptin and anti-ObRb-Ab. Leptin-induced platelet aggregation was dosedependently inhibited by U73122, AACOCF3, or Ro31-8220. The effect of leptin on intracellular calcium was inhibited in a dosedependent manner by incubation with U73122 and AACOCF3, but not with Ro31-8220. CONCLUSIONS: Our study confirms that leptin is able to enhance ADP-induced aggregation of human platelets, and raise the possibility that PLC, PKC, PLA 2 , and calcium could play a relevant role in mediating the proaggregating action of leptin.
Introduction
Leptin, the product of the ob gene, 1 is a protein secreted mainly by the adipose tissue, which signals the size of energy stores to the central nervous system; thus, affecting hypothalamic centres involved in the regulation of foodintake and energy balance. 2 Although leptin's major role seems to be in the regulation of body weight and energy metabolism, several evidences suggest that this hormone could be involved in other pathophysiological mechanisms. Leptin has been reported to regulate immune function, angiogenesis, bone formation, and fertility, and the expression of leptin receptor has been demonstrated in a variety of tissues. [3] [4] [5] [6] [7] [8] In the last few years it has been suggested that leptin may play a relevant role in the association between obesity and cardiovascular risk, 9 and a recent report of the West of Scotland Coronary Prevention (WOSCOP) Study showed that leptin is an independent risk factor for coronary heart disease. 10 Recent studies demonstrate that leptin is able to accelerate arterial thrombosis; thus, suggesting a mechanism for atherothrombotic disease in obesity. 11, 12 The long form of leptin receptor (ObRb) has been found on the platelet membrane, and it has been suggested that leptin may promote the aggregation of human platelets through the activation of its receptor and postreceptor phosphorylation of STAT proteins. 13 The ability of leptin to enhance platelet aggregation has been recently confirmed in ob/ob mice 11 and healthy subjects. 14 However, little is known about the possibility whether post-receptor second messengers other than phosphorylated STAT proteins could be involved in mediating leptin effects on platelet aggregation. Phospholipase C (PLC), protein kinase C (PKC), calcium, and phospholipase A 2 (PLA 2 ) are established modulators of platelet function. 15 We hypothesized that these pathways could be involved in leptin-dependent platelet aggregation, 16 and we recently reported on the putative role of PLC in mediating leptin effects on platelet aggregation induced by adenosine diphosphate (ADP). 17 The aim of the present study was to investigate the role of PLC, PKC, calcium, and PLA 2 in mediating leptin-dependent aggregation of human platelets.
Methods
After obtained their written informed consent, 14 healthy normal-weight male (age 31.471.9y; body mass index 22.770.6 kg/m 2 ) subjects were enrolled in the study. All subjects were selected from the staff of the University Hospital of Messina, Italy, and underwent a complete clinical and laboratory assessment to exclude major health problems. In order to participate in the study, all subjects were requested not to take drugs in the 4 weeks before sampling.
After overnight fasting, a venous blood sample was obtained in the supine position from the cubital vein of the arm in all subjects, using a cannula that had been placed 30 min before sampling to avoid the stress of venipuncture, and maintained by slow infusion of saline solution (0.5 ml/ min). For platelet study, blood samples (25 ml) were collected in a conical polipropylene tube containing 3.33 ml/l of ACD (consisting of 64 mmol/l citric acid, 85 mmol/l sodium citrate, and 111 mmol/l dextrose). An aliquot (5 ml) was separately collected in ACD, and plasma obtained by centrifugation was used for the assay of plasma leptin (Human Leptin RIA kit, Linco Research Inc., St Charles, MO, USA) concentrations. Only subjects with normal plasma leptin concentrations were enrolled in the study (plasma leptin levels 3.870.5 ng/ml).
Platelet-rich plasma (PRP) was obtained by centrifugation at 800 g for 20 min at 41C. The PRP was centrifugated at 2000 g at 41C to form a soft platelet pellet, resuspended in HEPES Tyrode's buffer (HBS) consisting of 145 mmol/l NaCl, 5 mmol/l KCl, 0.5 mmol/l NaH 2 PO 4 , 1 mmol/l MgSO 4 , 5.5 mmol/l glucose, 3.0 mg/l BSA, 10 mmol/l HEPES, pH 7.4, and washed once. Centrifugation was performed at 41C in order to minimize spontaneous platelet activation. 18 Measurements were successively carried out at room temperature.
Platelets were counted by a Coulter counter (Coulter International Corporation, Miami, FL, USA) and resuspended in HBS buffer at a concentration of 0. To study leptin effects on agonist-induced aggregation, 0.4 ml of platelet suspension was preincubated with leptin 5-500 ng/ml (Linco Research Inc., St Charles, MO, USA) for 5 min, and then stimulated by the addition of ADP (Sigma Chemical Co, St Louis, MO, USA) 2 mM, (Sigma Chemical Co St Louis, MO, USA).
Platelet Ca 2 þ concentrations were measured either with or without stimulation by ADP 2 mM, before and after preincubation of platelet suspension with leptin 5-500 ng/ml for 30 min.
To evaluate the role of the long form of leptin receptor (ObRb) in mediating leptin effects on platelet aggregation and Ca 2 þ concentrations, platelets were preincubated with leptin alone (50 and 100 ng/ml) or leptin 100 ng/ml and rabbit anti-human leptin receptor long form antibody (ObRb-Ab) 1.25, 2.5, 5 and 10 ml, which corresponded to a dilution of 1:800, 1:400, 1:200 and 1:100, respectively. The anti-ObRb antibody used in these experiments is a policlonal antibody produced by rabbit against the C-terminal human leptin receptor conjugated to carrier protein (Linco Research Inc., St Charles, MO, USA). Furthermore, in order to investigate the role of enzymatic pathways involved in leptin-dependent aggregation and calcium mobilization, platelets were preincubated with the inhibitor of PLC U73122 3.125, 6.25, 12.5 and 25 mM, 19 inhibitor of PLA 2 AACOCF3 1.25, 2.5, 5 and 10 mM, 20 and inhibitor of PKC Ro31-8220 (Calbiochem, San Diego, CA, USA) 1.25, 2.5, 5 and 10 mM, 20 for 3 min at 371C, and then stimulated with leptin (50 or 100 ng/ml) and ADP. Statistical analysis was performed using ANOVA one-way test with Scheffè post hoc test for multiple comparisons or ttest for unpaired data when appropriate. Data were expressed as mean7s.e.m. Two-tailed values of Po0.05 were considered statistically significant. All statistical procedures were performed using the SPSS V 10.0 statistical software package (SPSS Inc., Chicago, IL, USA).
Results
The effect of leptin (5-500 ng/ml) on ADP-induced platelet aggregation is shown in Figure 1 . The stimulation of platelets with either ADP or leptin alone did not produce any change in % maximal aggregation with respect to aggregation Platelet aggregation showed a slow and nearly linear increase until maximum was reached at a time point near 400 s with either vehicle or leptin alone. Conversely, with ADP alone % maximal aggregation was reached within the first 3 min. Platelet preincubation with leptin led to a significant and dose-dependent increase in ADP-induced platelet aggregation. Figure 2 shows the effects of leptin (5-500 ng/ml) on platelet Ca 2 þ concentrations, with and without stimulation by ADP 2 mM. The incubation with leptin induced a dosedependent increase in platelet free calcium, which became statistically significant at 10 ng/ml leptin concentration. After stimulation by ADP, platelet free calcium concentrations were always significantly higher with respect to those observed without ADP. In order to ascertain whether leptin effects were mediated by the activation of the ObRb on platelet membrane, we measured platelet aggregation after incubation with leptin alone or in combination with the antibody against the ObRb, and found that leptin effects on platelet aggregation were completely abated by the co-incubation with leptin and anti-ObRb antibody (1:200 and 1:100 dilutions). The incubation with anti-ObRb antibody alone did not produce any effect on platelet aggregation induced by ADP 2 mM (Table 1) .
Similarly, the rise in platelet free calcium concentration induced by leptin was completely abolished in the presence of the anti-ObRb antibody (1:200 and 1:100 dilutions), either with or without stimulation by ADP (Table 2) .
To investigate the role of PLC, PKC, and PLA 2 in leptindependent platelet aggregation, we measured platelet aggregation after incubation with leptin alone or in combination with the inhibitors of cytosolic enzymatic activities. The inhibition of PLC by U73122 was able to abolish leptin effect on platelet aggregation in a dose-dependent manner. Similar results were obtained when platelet suspensions were incubated with the inhibitor of PLA 2 AACOCF3 or the inhibitor of PKC Ro31-8220. Furthermore, platelet aggregation induced by ADP 2 mM remained unchanged when platelets were incubated with inhibitors alone (Table 3) .
We also studied the effect of inhibitors on leptin-induced increase in platelet Ca 2 þ concentration, and we found that the effect of leptin on intracellular calcium was dosedependently abated by incubation with U73122 and AA-COCF3, but not with Ro31-8220 (Table 4 ). In the light of these findings, we tried to verify whether the simultaneous addition of low concentrations of U73122 (3.125 and Leptin and platelet aggregation A Corsonello et al 6.25 mM) and Ro31-8220 (1.25 and 2.5 mM) had an additive effect on platelet calcium. However, we did not find any significant inhibitory effect in the latter experiment. Finally, inhibitors alone did not produce any effect on platelet calcium concentrations measured both with and without ADP ( Table 4) .
Discussion
Platelet activation is known to be involved both in the early and advanced stages of atherosclerosis. 21 Rising evidences suggest that leptin may contribute to the development of cardiovascular complications from obesity in humans. 9, 10 Thus, the study of leptin effects on platelet function may provide new insights into the mechanisms linking obesity and cardiovascular diseases.
In agreement with previous studies, 13,14 our results confirm that leptin is able to potentiate platelet aggregation response to ADP in healthy subjects. Platelets were shown to express the long form of leptin receptor (ObRb), and it has been demonstrated that the activation of platelet ObRb is directly coupled to the activation of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins, with a consequent activation of tyrosine phosphorylation. 13 Similarly, a significant enhancement of platelet aggregation response to ADP has been shown in ob/ob, but not in db/db (ie leptin-receptor deficient) mice.
11
In our study, the incubation of platelets with leptin alone resulted in about 20% maximal aggregation, with a nearly linear aggregation curve similar to that observed with buffer alone. These results are not surprising, since Nakata et al 13 reported about 10% of platelet aggregation with either vehicle and leptin 100 ng/ml, with a nearly linear aggregation curve. Another study of ours reported about 15% of maximal aggregation with leptin 100 ng/ml.
14 This phenomenon cannot be considered as an expression of a direct agonist effect of leptin on platelets, and is clearly different from the peak of aggregation measure obtained within 3 min with ADP 2 mM. The inhibition of PLC, PKC, and PLA 2 by U73122, Ro31-8220 and AACOCF3, respectively, was able to abolish the effect of leptin on platelet aggregation. Mounting evidences suggest that leptin may exert its biological action through the activation of intracellular pathways other than JAK-STAT tyrosine phosphorylation, which was formerly indicated as the unique second messenger system affected by the hormone. In fact, it has recently been demonstrated that leptin is able to activate PLC, mitogen-activated protein kinase (MAPK), and voltage-dependent calcium channels in cultured adrenal medullary chromaffin cells. 22 In agreement Leptin and platelet aggregation A Corsonello et al with this novel finding, our results raise the possibility that leptin may exert its enhancing effect on ADP-induced platelet aggregation through the activation of the PLC, PKC and PLA 2 pathways. The activation of PLC is an early key component in the stimulation of several cell types, including platelets, induced by a wide variety of agonists. [23] [24] [25] The activation of PLC leads to the hydrolysis of phosphatidylinositol 4,5 diphosphate, which, in turn, results in the formation of 1,2-diacylglycerol (DAG) and inositol 1,4,5 triphosphate (IP 3 ) 23, 24 : DAG is known to stimulate PKC and PLA 2 15,26 ; IP 3 is able to mobilize intracellular calcium. 27 PKC, PLA 2 and IP 3 act sinergistically to induce platelet activation including aggregation, secretion of alpha-and dense-granule contents, formation of thromboxan A 2 (TxA 2 ) and expression of adhesive receptors. 15, 23, 24, 28 In our study, the incubation with leptin was also able to produce a significant and dose-dependent increase in platelet free calcium concentrations, both in the presence and in absence of ADP. Platelet Ca 2 þ is known to represent an important step in platelet functional changes leading to platelet activation. Platelet agonists can induce a rise in cytosol Ca 2 þ levels: (1) further contributing to platelet activation and calcium mobilization. 31 Interestingly, leptin was able to increase platelet free calcium without ADP stimulation. However, when platelets were stimulated with both leptin and ADP, platelet calcium concentrations were significantly higher than those measured without ADP stimulation. Thus, it is conceivable that it is the presence of low-dose ADP that triggers the sensitization of platelets to leptin effects on both platelet aggregation and calcium mobilization. Our study shows that leptin-induced increase in platelet free calcium concentration is completely abated by coincubation with the ObRb antibody, PLC inhibitor U73122, or PLA 2 inhibitor AACOCF3. These findings, together with the recent demonstration that leptin is able to cause a sustained increase in intracellular calcium in cultured porcine adrenal medullary chromaffin cells through the activation of the ObRb receptor, 22 suggests that changes in platelet free calcium concentrations may be directly coupled to the leptin activation of PLC and PLA 2 , and strengthens the hypothesis that leptin-induced calcium mobilization may be involved in platelet aggregation response to leptin. Interestingly, the treatment of platelets with Ro31-8220 was able to inhibit leptin-dependent platelet aggregation, while leptin-induced increase in platelet calcium concentrations remained unaffected. This finding suggests that PKC activation and mobilization of intracellular calcium may represent two independent pathways involved in leptindependent platelet aggregation. This hypothesis is in agreement with a recent study demonstrating that human platelets contain a calcium-and a PKC-regulated pathway, downstream of PLC activation, which independently regulate agonists-induced fibrinogen receptor activation. 32 Although we failed to find an additive effect with low doses of PLC and PKC inhibitors on platelet calcium mobilization, this issue needs to be investigated further.
Limitations of our study deserve consideration. Our data are based on in vitro platelet aggregation, thus we can only hypothesize the existence of a pathomechanism linking leptin to the excess risk of thrombotic complications from obesity. Furthermore, since our study was performed by using inhibitors of cytosol enzymatic activities, we cannot rule out the possibility that the effect of these inhibitors is not a direct one, but secondary to effects on other pathways, for example, MAPKs. 33, 34 In conclusion, our study confirms that leptin is able to enhance ADP-induced aggregation of human platelets. Furthermore, it suggests that PLC, PKC, PLA 2 and calcium Leptin and platelet aggregation A Corsonello et al could play a relevant role in mediating the proaggregating action of leptin. Although these findings should be considered preliminary, our results provide further insight into the mechanism of leptin-dependent platelet aggregation.
